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Abstract
Background: We examined the use of male condoms and the diaphragm following completion of a clinical trial
of the diaphragm’s HIV prevention effectiveness. In the trial, called Methods for Improving Reproductive Health in
Africa (MIRA), women were randomized to a diaphragm group (diaphragm, gel and condoms) or a condom-only
control group. At trial exit, all women were offered the diaphragm and condoms.
Methods: Our sample consisted of 801 Zimbabwean MIRA participants who completed one post-trial visit (median
lapse: nine months; range two to 20 months). We assessed condom, diaphragm and any barrier method use at last
sex act at enrolment, final MIRA and post-trial visits. We used multivariable random effects logistic regression to
examine changes in method use between these three time points.
Results and discussion: In the condom group, condom use decreased from 86% at the final trial visit to 67% post
trial (AOR = 0.20; 95% CI: 0.12 to 0.33). In the diaphragm group, condom use was 61% at the final trial visit, and
did not decrease significantly post trial (AOR = 0.77; 95% CI: 0.55 to 1.09), while diaphragm use decreased from
79% to 50% post trial (AOR = 0.18; 95% CI: 0.12 to 0.28). Condom use significantly decreased between the
enrolment and post-trial visits in both groups. Use of any barrier method was similar in both groups: it significantly
decreased between the final trial and the post-trial visits, but did not change between enrolment and the post-trial
visits.
Conclusions: High condom use levels achieved during the trial were not sustained post trial in the condom
group. Post-trial diaphragm use remained relatively high in the diaphragm group (given its unknown effectiveness),
but was very low in the condom group. Introducing “new” methods for HIV prevention may require time and user
skills before they get adopted. Our findings underscore the potential benefit of providing a mix of methods to
women as it may encourage more protected acts.
Background
Condom promotion is a central component of a com-
prehensive prevention package offered to participants in
HIV prevention trials of female-initiated barrier meth-
ods. Long-term effects of such intensive promotion on
sustained condom use after trial completion is a critical
yet insufficiently examined area as it could inform con-
dom rollout programmes, as well as operations research
after demonstration of new, successful biomedical inter-
ventions. To our knowledge, only one study examined
condom use prevalence following participation in a
sexually transmitted infection (STI) and HIV prevention
trial. This trial of nonoxynol-9 gel against STI infection,
conducted among Cameroonian sex workers, found
decreased reports of condom use one year following
trial exit [1].
Here, we present data on barrier method use several
months after the Methods for Improving Reproductive
Health in Africa (MIRA) trial among Zimbabwean parti-
cipants recruited from the general population. The
MIRA trial evaluated the effectiveness of the diaphragm
against HIV/STI acquisition. Diaphragms are commer-
cially available worldwide as one of the oldest contra-
ceptive methods [2]. As previously described [3], during
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sive HIV prevention package consisting of: pre-test and
post-test counselling about HIV and STIs; testing and
treatment of curable STIs; and intensive risk-reduction
counselling that included education, demonstration and
promotion of male condom use during every sex act,
provision of free male condoms, and provision of a fact
sheet with instructions on how to use condoms.
All volunteers were also fitted with diaphragms,
received instructions and practiced insertion of the dia-
phragms at the clinic to ensure that women in the dia-
phragm group were not inherently better at using the
diaphragm than those in the condom group. After ran-
domization, women in the diaphragm group received
education and counselling about the diaphragm and a
product instruction sheet. HIV/STI testing and counsel-
ling and risk-reduction counselling were repeated at
every follow-up visit, as was product counselling (con-
doms or condoms and diaphragm) as appropriate for
group assignment.
Main results from the trial have been previously pub-
lished, and no significant protective effect of the inter-
vention against HIV or STI could be demonstrated
[3-5]. We also previously examined diaphragm adher-
ence in the MIRA intervention sample [6]. For this ana-
lysis, we focused on post-trial use of male condoms,
diaphragms and any barrier methods (condoms and/or
diaphragm) among Zimbabwean MIRA participants.
Specifically, we assessed post-trial use compared with
use during the trial. Additionally, we compared post-
trial use with that reported at trial enrolment.
Methods
This analysis draws data from the MIRA trial, an open-
labelled, multisite, randomized, controlled trial of the
diaphragm and Replens® lubricant gel in South Africa
and Zimbabwe. It also draws data from an ancillary
study, which consisted of a cross-sectional post-trial
study visit among a subset of former MIRA participants
at the Zimbabwean site to validate reports of recent sex-
ual activity and method use using a biomarker of semen
exposure (prostate-specific antigen). Detailed methods
for recruitment, eligibility criteria, study procedures and
main findings for both these studies have been pub-
lished elsewhere [3,7].
Study setting and population
The MIRA trial was conducted between 2003 and 2006
(registration with http://ClinicalTrials.gov, number
NCT00121459). Women were recruited from reproduc-
tive and general health clinics and the community. Elig-
ibility criteria included being: 18-49 years old; HIV
uninfected; non-pregnant; sexually active; free of treata-
b l eS T I s ,w i t hah e a l t h yc e r v i x ;a n da b l et oi n s e r tt h e
diaphragm prior to randomization. Participants were
seen at two study clinics within 30 kilometres of Harare
(Chitungwiza, a peri-urban municipality, and Epworth, a
slightly poorer and less developed suburb), and followed
between 12 and 24 months (depending on their calendar
date of enrolment). The retention rate for MIRA
Zimbabwean participants was 94.2%.
Study procedures
At MIRA screening, following written informed consent,
all volunteers provided demographic information,
received HIV/STI testing and counselling, received treat-
ment of curable STIs, and were provided with free male
condoms [3]. Approximately two weeks after screening,
eligible women returned for their enrolment visit and
were randomized into a diaphragm group (receiving dia-
phragm, gel and male condoms) or a condom group
(receiving male condoms only). At enrolment and
quarterly thereafter, participants received: behavioural
assessments in their native language using Audio Com-
puter-Assisted Self-Interviewing (ACASI); HIV testing
with pre- and post-test counselling; risk-reduction coun-
selling that included use of male condoms during every
sex act; and free male condoms.
Diaphragm education and provision All women were
fitted by a trained study clinician, received a diaphragm
educational session, and successfully practiced dia-
phragm insertion and removal at the clinic prior to ran-
domization. Additionally, women in the diaphragm
group received quarterly diaphragm adherence counsel-
ling, as previously described [6]. So as not to discourage
participation among women randomized to the control
group, and because the study products were commer-
cially available, all participants were told they could
obtain diaphragms and gel after study completion.
Trial exit procedures All participants received free
male condoms at their MIRA exit visit, and were
encouraged to return to the clinic for resupply of con-
doms. At MIRA study exit, women in the diaphragm
group could elect to keep their study diaphragms or be
refitted and receive new devices (if they had been fitted
a year or more previously) and receive a year’ss u p p l yo f
study gel (commensurate with their coital frequency).
Similarly, women in the condom group could elect to
take study diaphragms, and each of those interested was
fitted, received a diaphragm and a supply of study gel.
All exiting participants who elected to keep or receive
diaphragms received a comprehensive educational ses-
sion, emphasizing that trial results were not yet known
and reviewing what was known and unknown about the
diaphragm. Before supplies were dispensed, participants
completed a comprehension quiz and had to demon-
s t r a t ef u l lu n d e r s t a n d i n gt h a ti tw a sn o tap r o v e n
method for HIV/STI prevention or contraception (when
used with a non-spermicidal gel) [8].
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cussed extensively by the study’s scientific team and
approved by all institutional review boards, community
advisory boards and ethical consultants to the study. In
late July and August 2007, when participants were
informed of the final MIRA trial results, which showed
no effect of the intervention, participants were discour-
aged to continue use of the diaphragm. Staff attempted
to contact all participants and invited them to come to
the study results meetings at which investigators
explained the results and answered questions. The post-
study visit described in the next section took place prior
to the release of trial findings.
Post-trial visit
We conducted a cross-sectional ancillary study to vali-
date self-reports of recent sexual activity using a bio-
marker, which included one post-trial visit conducted
between December 2006 and June 2007, and enrolled a
subset of MIRA participants from Zimbabwe. Only non-
pregnant, former MIRA participants without a vaginal
delivery or third-trimester stillbirth in the prior six
weeks were eligible for enrolment. Women learned
about this ancillary study at their last MIRA visit,
through community outreach or during drop-in clinic
visits that occurred after completing the trial (e.g., to
obtain additional condoms). For the ancillary study,
women were randomized in approximately equal num-
bers into one of two interview modalities: ACASI (n =
450) or face-to-face interview (FTFI) (n = 460). Since
the baseline characteristics of women in the ACASI and
FTFI groups were similar and results from the two mod-
alities were not statistically different [7], we conducted
combined analysis of all behavioural responses from the
ancillary study. Nonetheless, we adjusted for interview
mode at the post-trial visit in all multivariable analyses
to control for possible unmeasured confounding.
Study sample
The original ancillary study included 910 former MIRA
Zimbabwean participants [7]. Of those, 840 had sex
since completing the MIRA study (92.3%); 803 had not
HIV seroconverted during the MIRA trial; and 801
women, our final analysis sample, had condom use data
at one or more MIRA follow-up visits (see Figure 1).
Measures
Barrier method(s) use at last sex act was assessed at
enrolment, at every MIRA quarterly visit (using ACASI)
and at the post-trial visit (using ACASI or FTFI). For
this study, our main outcome measures were: (a) male
condom use at last sex act (yes/no); (b) protected last
sex act by a barrier method (male condom, female con-
d o mo rd i a p h r a g m )( y e s / n o ) ;a n d( c )f o rM I R Ad i a -
phragm group participants only, diaphragm use at last
sex (yes/no).
Exposure measures We created binary indicator vari-
ables for each study visit type. For our primary analysis,
we compared method use at the last MIRA follow-up
visit versus the post-trial visit. Second, we compared
method use at MIRA enrolment versus post trial.
Covariates Because we hypothesized that the time lapse
between the final MIRA follow-up visit and the post-
trial visit could affect reported method use, we created a
continuous time since exit indicator variable by calculat-
ing the time (in months) between a participant’sl a s t
MIRA study visit and her post-trial visit (range: two to
20 months). To assess a dose effect from repeated coun-
selling at regular MIRA visits, we also created a continu-
ous variable of the number of completed quarterly
follow-up visits in MIRA that a participant had received
(range: one to eight). In all multivariable analyses, we
controlled for post-trial visit interview mode (ACASI vs.
FTFI) and age (as a continuous measure). We also
examined the following additional potential confoun-
ders: baseline education, marital status, cohabitation
Figure 1 Study sample flow chart. *This includes women who
remained HIV seronegative throughout the duration of the trial, and
excludes those (n = 31) who had no MIRA follow-up data.
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new partner during the MIRA trial. We found no evi-
dence that these additional covariates confounded the
main associations of interest and thus did not include
them in the multivariable analyses. To address possible
confounding from acquiring an STI during the trial, we
conducted a sensitivity analysis where participants who
were diagnosed with chlamydia, gonorrhea or trichomo-
nas during MIRA were removed from the sample. The
results were essentially identical (data not shown).
Analyses
Preliminary analyses were descriptive and focused on
the proportion of participants at a given visit type who
used a specific barrier method (male condom; dia-
phragm; female condom) or any barrier method at last
sex. At baseline, we examined socio-demographic differ-
ences and behavioural characteristics between our study
sample and the remaining Zimbabwe MIRA sample,
using chi-square tests for categorical variables, t-tests or
Wilcoxon rank-sum tests for continuous variables, and
Poisson regression for count variables.
To examine changes between visits in method(s) used
at last sex, we compared study outcomes for each parti-
cipant at the last MIRA follow-up visit and the post-
trial visit, using multivariable random effects logistic
regression models. As we anticipated differing patterns
in each MIRA study group, separate models were run
for the diaphragm and the condom groups. Using a
similar approach, we also examined change in method(s)
used at last sex between MIRA enrolment and the post-
trial visit. All analyses were conducted using SAS ver-
sion 9.1 (SAS Institute, Inc., Cary, NC, USA).
Ethical approval
All participants provided written informed consent prior
to participating in MIRA and the ancillary study. The
following local ethics committees at collaborating insti-
tutions gave approval for the studies: the institutional
review boards at the University of California, San Fran-
cisco; the Medical Research Council of Zimbabwe; the
Medicines Control Authority of Zimbabwe; the Western
IRB; and Family Health International. The MIRA study
is registered with http://ClinicalTrials.gov (number
NCT00121459).
Results
Study sample
This analysis includes data from 801 former MIRA trial
Zimbabwean participants. As shown in Table 1, the
majority of the women were 25 years old and above,
and more than half had not completed high school.
Women had a median of one lifetime partner (range:
o n et of i v e )a n da l m o s ta l lw e r em a r r i e da n dc o h a b i t a t -
ing with their partners. More than three-quarters used
hormonal contraceptives at baseline, and the
distribution of contraceptive method use was similar at
trial exit. “Ever use” of male condoms increased from
65.5% at screening to 91.0% at enrolment (McNemar
t e s t ,p<0 . 0 0 0 1 ) .A te n r o l m e n t ,7 4 %r e p o r t e du s i n ga
barrier method at their last sex act, with 71.0% using a
male condom and 3.4% a female condom. Women com-
pleted a median of eight quarterly follow-up visits dur-
ing MIRA (range: one to eight), and there was a median
of nine months (range: two to 20) between women’s
final MIRA visits and their post-trial visits.
This study sample was very similar to MIRA Zimbab-
wean participants who did not participate in this study.
H o w e v e r ,w o m e ni nt h i ss t u d yw e r es l i g h t l yo l d e r
(32.6% were 18-24 vs. 38.1%; p = 0.02), had lower edu-
cational attainment (55.8% did not complete high school
vs. 49.1%; p = 0.02), were more consistent product users
(condoms: OR = 1.34, 95% CI: 1.18-1.53, and dia-
phragm: OR = 1.30, 95% CI: 1.09-1.54) and attended
more MIRA follow-up visits (median eight vs. six visits,
p < 0.0001) compared with MIRA Zimbabwean partici-
pants who did not join this study (data not shown).
Patterns of method(s) use at last sex
Male condoms
As shown in Figure 2a, group averages among women in
the MIRA condom group indicate that male condom
use at last sex increased between enrolment (73.8%) and
the first quarterly visit (86.7%), and decreased between
the MIRA 24-month visit (85.8%) and the post-trial visit
(67.4%). As reported for the multisite MIRA sample [3],
in the diaphragm group, condom use at last sex showed
a different temporal trend between MIRA enrolment
(68.0%), first quarterly visit (37.3%) and the 24-month
visit (65.2%); condom use also decreased at the post-
trial visit (56.2%).
Diaphragm
Only one woman reported ever using a diaphragm prior
to study entry (Table 1). At trial exit, almost all women
in the diaphragm group (n = 369; 96.9%) kept their dia-
phragms or elected to be fitted with new ones. As
shown in Figure 2b, in the diaphragm group, there was
a slight increase in diaphragm use at last sex during the
trial: from 77.7% at the first quarterly visit to 88.6% at
the 24-month visit, and then decreasing to 50.4% at the
post-trial visit. In the condom arm, 210 women (50%)
elected to be fitted for diaphragms at trial exit. Among
these, 31 (14.8%) reported using diaphragms at last sex
at their post-trial visit (Table 1).
Barrier method use (male condom, female condom and/or
diaphragm) at last sex act
As shown in Figure 2c, patterns of barrier method use
at last sex act were very similar between the diaphragm
and condom groups, showing the most increase between
enrolment and the first quarterly follow up. At the
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Study sample
n = 801 %
Baseline
Randomization arm Intervention 381 47.6
Control 420 52.4
Age group 18-24 261 32.6
25-34 379 47.3
35+ 161 20.1
Education (binary) <High school 447 55.8
Married Yes 775 96.8
Cohabitating Yes 777 97.0
Lifetime partners (1 vs. > 1) One lifetime partner 628 78.4
Ever had vaginal sex using a male condom (screening) Yes 525 65.5
Ever had vaginal sex using a male condom (enrolment) Yes 728 91.0
Condom use in the past 3 months (enrolment) Always 215 26.8
Sometimes 356 44.4
Never 230 28.7
Male condom use at last sex (enrolment) Yes 569 71.0
Ever female condom use (enrolment) Yes 58 7.2
Female condom use at last sex (enrolment) Yes 27 3.4
Last sex act protected by a barrier method (enrolment) Yes 590 73.7
Ever used diaphragm Yes 1 0.1
Coital frequency per week at screening (≤3, >3) ≤3 423 52.8
Main contraceptive at screening (#) Long term 25 3.1
Injectable 113 14.1
Pill 514 64.2
Barrier method 95 11.9
Other/none 54 6.7
MIRA follow up and exit
Number of quarterly follow-up visits in MIRA Mean; median (range) 6.83; 8 (1-8)
Ever had a new regular partner during MIRA trial Yes 212 26.5
Kept/took diaphragm at exit visit (entire sample) Yes 579 72.3
Kept/took diaphragm in intervention arm (at exit visit) n = 381 Yes 369 96.9
Took diaphragm in control arm (at exit visit) n = 420 Yes 210 50.0
Main contraceptive at exit visit (#) Long term 26 3.3
Injectable 139 17.4
Pill 457 57.1
Barrier method 108 13.5
Other/none 71 8.9
Post-trial study visit
Months between last MIRA visit and post-trial visit Mean; median (range) 9.41; 9 (2-20)
Total n n %
Male condom use at last sex 801 497 62.1
Female condom use at last sex 801 21 2.4
Diaphragm use at last sex (intervention arm) 381 192 50.4
Diaphragm use at last sex (intervention arm)* 369 190 51.5
Diaphragm use at last sex (control arm)* 210 31 14.8
Diaphragm and male condom use at last sex (intervention arm) 381 123 32.3
Diaphragm and male condom use at last sex (intervention arm)* 369 122 33.1
Diaphragm and male condom use at last sex (control arm)* 210 10 4.8
Protected last sex act 801 597 74.5
*among those who took/kept the diaphragm at MIRA exit visit.
(#) hierarchical categorization.
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and 87.4% in the condom group reported using a barrier
method at their last sex act. This decreased to 74.8%
and 74.3% at the post-trial visit, respectively. The mix of
barrier methods used at last sex for different visit types
(MIRA enrolment, final trial visit and post-trial visit) is
summarized in Figures 3a and b.
In the condom group, as expected, male condoms
contributed most to the barrier methods mix across all
visit types. In contrast, in the diaphragm group, at final
MIRA visit, 32% of last sex acts were protected by the
diaphragm only; this decreased to 18.1% at the post-trial
visit. Diaphragm and condom used together (per MIRA
protocol requirement) were reported by 46.5% partici-
pants at their last MIRA visits and by 32.3% at the post-
trial visit. In the diaphragm group, male condom used
alone was reported by 66.9% of women at enrolment,
13.1% at final trial visit and 23.6% at the post-trial visit.
Multivariable analysis of individual-level changes in
reported method use
Condom group
As shown in Table 2, between a participant’s last MIRA
visit and her post-trial visit, there was a significantly
decreased odds in her report of condom use at last sex
(AOR = 0.20; 95% CI 0.12-0.33; p < 0.0001) and of use
of any barrier method at last sex (AOR = 0.21; 95% CI
0.12-0.33; p < 0.0001). These findings were not affected
by the number of months between trial exit and the
post-trial visit, nor by the number of MIRA visits
attended.
Diaphragm group
As shown in Table 2, between a participant’s last MIRA
visit and her post-trial visit, there was a significantly
decreased odds in her report of diaphragm use at last
sex act (AOR = 0.18; 95% CI 0.12-0.28; p < 0.0001) and
of use of any barrier method at last sex (AOR = 0.15;
95% CI 0.08-0.27, p < 0.0001). Reported condom use at
last sex decreased non-significantly between these two
visit types. In the diaphragm group, the more MIRA vis-
its a woman attended, the more likely she was to report
use at last sex for each of the three outcomes: male con-
doms, diaphragm, and any barrier method. The number
of months between trial exit and the post-trial visit did
not influence these outcomes.
When assessing method use at enrolment compared
with the post-trial visit, similar results were found for
the condom and diaphragm groups (Table 2): there was
a significantly decreased odds in a woman’sr e p o r to f
condom use at last sex act. However, there was no dif-
ference in a woman’s odds of reporting any barrier
method use at enrolment and at her post-trial exit visit.
In the diaphragm group only, the number of MIRA vis-
its was associated with these outcomes, but not the
number of months between trial exit and the post-trial
visit.
Discussion
This study is among the few that report patterns of male
condom and other barrier method use by women after
participating in an HIV prevention trial. We compared
self-reported condom use at enrolment (but before ran-
domization), at the end of the trial, and several months
after trial completion. Because the diaphragm (our
investigational product) is commercially available, parti-
cipants who elected to do so were allowed, after careful
and comprehensive education and counselling, to take
Figure 2 Group averages in method(s) used at last sex, by
MIRA visits and post-trial visit. Figure 2a. Male condom use at
last sex by visit type and MIRA diaphragm and condom groups; n =
801 Figure 2b. Diaphragm use at last sex by visit type in MIRA
diaphragm group; n = 381 Figure 2c. Barrier method(s) use at last
sex act (male condom, female condom, diaphragm) by visit type
and MIRA diaphragm and condom groups; n = 801.
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unique data on intervention and post-intervention use
of the diaphragm.
In the condom group, reported condom use at last sex
significantly decreased between the MIRA last study
visit and the post-trial visit. Furthermore, there was a
small but significant decrease between condom use at
MIRA enrolment compared with the post-trial visit.
Also, more MIRA visits did not influence reported con-
dom use, nor did the time elapsed between MIRA exit
and the post-trial visit. Taken together, these results
suggest that there was no sustained effect of repeated
counselling on condom use after the counselling and
study participation stopped. At MIRA trial exit, women
received condoms and were encouraged to return to the
clinic for additional free condoms. They also were
provided with referrals for obtaining condoms free of
charge. Still, passive access may not have been sufficient
to maintain high levels of condom use post trial, and
women or partners’ willingness to use condoms after
the trial may have decreased. During the trial period,
sustained behaviour change may have been maintained
by regular HIV testing, ongoing risk-reduction counsel-
ling, perceived obligation among participants and their
partners to use condoms while in the study, as well as
free condom provision.
Diaphragms were evaluated in MIRA for disease pre-
vention, and were mostly unavailable and virtually
unused as contraceptives in the geographical areas
where the trial was conducted [9]. This gave us a unique
opportunity to assess uptake and post-trial use of a pre-
viously unknown female-initiated method. Based on the
Figure 3 Last sex act by barrier method used and by visit type. Figure 3a. Last sex act by barrier method used and by visit type
among diaphragm group participants; n = 381 Figure 3b. Last sex act by barrier method used and by visit type among condom group
participants; n = 420.
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Change in condom use and use of any barrier method at last sex, among condom group participants (n = 420)
Last MIRA Follow-up Visit Last FU visit Post-trial visit OR Lower limit Upper limit p value
n % n %
model 1 Condom use at last sex 363 86.43 283 67.38
Visit type* 0.20 0.12 0.33 <0.0001
Time since trial exit 0.95 0.88 1.03 0.228
Number of MIRA visits 1.01 0.84 1.22 0.8899
model 2 Any barrier method 374 89.05 312 74.29
Visit type* 0.21 0.12 0.35 <0.0001
Time since trial exit 0.96 0.88 1.05 0.347
Number of MIRA visits 0.93 0.75 1.16 0.5293
MIRA Enrolment Visit Enrolment visit Post-trial visit AOR Lower limit Upper limit p value
n % n %
model 1 Condom use at last sex 310 73.81 283 67.38
Visit type** 0.66 0.46 0.93 0.0196
Time since trial exit 0.96 0.90 1.02 0.1824
Number of MIRA visits 1.07 0.91 1.25 0.4349
model 2 Any barrier method 323 76.9 312 74.29
Visit type** 0.83 0.58 1.19 0.3178
Time since trial exit 0.96 0.90 1.02 0.2077
Number of MIRA visits 1.02 0.87 1.20 0.7732
Change in diaphragm, condom use and use of any barrier method at last sex, among diaphragm group participants (n = 381)
Last MIRA Follow-up Visit Last FU visit Post-trial visit AOR Lower limit Upper limit p value
n % n %
model 1 Diaphragm at last sex 303 79.53 192 50.39
Visit type* 0.18 0.12 0.28 <0.0001
Time since trial exit 0.95 0.89 1.01 0.1058
Number of MIRA visits 1.28 1.09 1.49 0.0024
model 2 Condom use at last sex 231 60.63 214 56.17
Visit type* 0.77 0.55 1.09 0.1425
Time since trial exit 1.03 0.96 1.10 0.4054
Number of MIRA visits 1.26 1.07 1.49 0.0062
model 3 Any barrier method 357 93.7 285 74.8
Visit type* 0.15 0.08 0.27 <0.0001
Time since trial exit 0.93 0.86 1.00 0.0593
Number of MIRA visits 1.29 1.07 1.55 0.0072
MIRA Enrolment Visit Enrolment visit Post-trial visit AOR Lower limit Upper limit p value
n % n %
model 1 Condom use at last sex 259 67.98 214 56.17
Visit type** 0.55 0.39 0.76 0.0004
Time since trial exit 0.99 0.94 1.05 0.7865
Number of MIRA visits 1.18 1.03 1.36 0.0153
model 2 Any barrier method 267 70.08 285 74.8
Visit type** 1.33 0.93 1.89 0.1134
Time since trial exit 0.96 0.90 1.02 0.1764
Number of MIRA visits 1.16 1.00 1.34 0.0553
AOR = adjusted odds ratio; CL = confidence limit; FU = follow up.
*post-trial visit vs. last MIRA follow-up visit.
**post trial visit vs. MIRA enrolment visit.
All models are controlling for age and substudy interview mode group (ACASI vs. FTF I).
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and given that the device is safe and commercially avail-
able, each woman was allowed to take a diaphragm at
trial exit. Unfortunately, when trial results became avail-
able, findings failed to demonstrate significant protec-
tion to users, and participants were advised to stop
using the device.
Only half of the condom group elected to take dia-
phragms at MIRA trial exit, and of those, a small minor-
ity reported using them at their post-trial visit. This is
not surprising as diaphragms were provided at MIRA
exit with a great deal of cautionary information, empha-
sizing their unknown effectiveness against HIV/STIs or
pregnancy (when used without a contraceptive gel).
Interestingly, most women in the diaphragm group, who
received the same exit information and education, chose
to keep and/or take the diaphragms at trial exit, and
half still reported diaphragm use (at last sex) several
months after the trial. We interpret this as an indication
of genuine acceptability of the device among users, and
this is corroborated by high reported acceptability dur-
ing the trial [10] and in other studies of cervical barriers
[11,12]. Alternatively, our exit product education and
counselling may have been less effective than intended.
T h ed i f f e r e n c ei nd i a p h r a g mu s ea tt h ep o s t - t r i a lv i s i t
between the condom and diaphragm groups, both of
which had the option of receiving diaphragms at their
exit visit, highlights that access and basic skills taught at
t h ec l i n i cm a yn o tb es u f f i c i e n tf o ru p t a k eo fan e w
method and that “real-life” experience, along with
ongoing support, may better ensure uptake and contin-
ued use. Previous reports from other developing coun-
tries indicate that adequate information and support, as
well as good user skills, are required to ensure dia-
phragm uptake and to avoid high discontinuation rate
as a contraceptive [13,14]. Additionally, in a previous
Zimbabwean study assessing the diaphragm as a poten-
tial disease prevention method, problems with the device
significantly decreased over time, suggesting that prac-
tice with the device and educational follow-up will help
improve user skills [11].
Reported use of any barrier method at last sex was
h i g h e s t( a l m o s t7 5 % )a tt h ep o s t - t r i a lv i s i t ,a n dc o m -
pared with MIRA trial exit visit levels, it decreased less
than condom or diaphragm use individually. Further-
more, levels were similar to those reported at MIRA
enrolment for women in both the condom group and
the diaphragm group. As has been shown in other stu-
dies, expanding the mix of methods increases method
coverage [15,17].
We previously reported that protocol-required concur-
rent use of two barrier methods (male condoms and
diaphragms) proved challenging during the trial, as
highlighted by a drop in reported male condom use in
the diaphragm group during MIRA follow up [18,19].
This drop was most pronounced at the first quarterly
follow-up visit; then there was a gradual increase in con-
dom use over the MIRA follow-up period, although
reported condom use in the diaphragm group never
reached enrolment levels. Our data suggest that in the
diaphragm group, more exposure to testing, counselling
and educational messages was associated with an
increased likelihood of reporting use of male condoms,
diaphragms or any barrier method. Since women in the
diaphragm group were introduced to a “new” method,
repeated education and adherence counselling may have
translated into progressive skill acquisition and
increased use. Ongoing support and counselling may
have also somewhat encouraged condom use after the
initial drop, possibly by helping women to overcome
some of the challenges they faced with concurrent use
of diaphragms and condoms [19].
There are several limitations to this study. Most
importantly, method(s) use was self-reported and may
have been influenced by recall and social desirability
b i a s e s .W eo n l ye x a m i n e dp r o d u c tu s e“at last sex”
because others have reported that it is representative of
behaviour over longer time periods, such as “use in the
last three months” (Ben Masse, personal communica-
tion, 2008 and [20]), but minimizes recall bias.
Second, we cannot tease out if the increase in condom
use reported during MIRA follow up in the condom
group was due to the effect of condom counselling, a
trial effect, or to over-reporting of a socially desirable
behaviour. Although results from the ancillary study
indicate that self-reported condom use was likely
inflated [7], we didn’te x p e c tt h i sb i a st ob ed i f f e r e n t i a l
between visit types, and thus, individual-level analyses of
relative changes over time should still provide useful
insights into participants’ behaviour. The same holds
true for diaphragm reports in the diaphragm group.
Indeed, because MIRA enrolment occurred after one or
more screening visits involving intensive interaction
with clinical staff, and the post-trial visit was conducted
at the MIRA study clinic with the same clinical staff, we
had no reason to expect that if misreporting occurred, it
would significantly differ by visit type.
Third, we started assessing our behavioural measure of
method use at last sex at the enrolment visit, after
women had already been screened, HIV tested and
counselled about condoms. Thus, the baseline condom
use reported here was likely higher than in a study-
naïve population, and indeed, we did observe that “ever
use of condoms” significantly increased between MIRA
screening and enrolment visits [3]. Thus, post-trial use
of condoms, though lower than use during the trial
might have remained higher than condom use prior to
study entry. It is not clear what would help sustain male
van der Straten et al. Journal of the International AIDS Society 2010, 13:39
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level of services, including counselling, should be con-
tinued beyond the duration of the trial.
Somewhat unexpectedly, diaphragm use persisted after
women exited the trial, especially among women in the
diaphragm group who were experienced users. Thus,
availability of trained staff for support, user skills and
habituation may be important for sustaining “new” pro-
duct use. In contrast to condoms, access to a diaphragm
did not present a barrier to use since it is reusable, and
this may have facilitated continued use after the trial.
Conclusions
High condom use levels achieved during the trial were
not sustained post trial in the condom group. Post-trial
diaphragm use remained relatively high in the dia-
phragm group (given its unknown effectiveness), but
was very low in the condom group. Introducing “new”
methods for HIV prevention may require time and user
skills before they get adopted. Our findings underscore
the potential benefit of providing a mix of methods to
women as it may encourage more protected acts. We
anticipate that the findings presented here may inform
better design of behavioural research in the context of
biomedical clinical trials, which will generate more reli-
able and useful outcomes to guide operations research
and programmatic rollouts.
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